The FDA has approved Dalvance (dalbavancin), from Durata Therapeutics, for injection for the treatment of adult patients with Acute Bacterial...
Actavis plc , a leading global specialty pharmaceutical company, and Durata Therapeutics, Inc. , an innovative pharmaceutical company focused on...
DUR 001-303 Study Meets Primary & Secondary Endpoints--- Actavis plc has announced positive top-line results for study DUR001-303, a phase...
Allergan has announced that the FDA has accepted for filing Allergan's supplemental New Drug Application (sNDA) to expand the label...
Actavis plc announced that the European Commission has granted Actavis' subsidiary Durata Therapeutics International B.V., marketing authorization for Xydalba (dalbavancin)...
Cardiome Pharma Corp. announced that it has launched Xydalba (dalbavancin) in the UK earlier than expected. The European Medicines Agency...